121 related articles for article (PubMed ID: 11504826)
21. Determinants of paclitaxel penetration and accumulation in human solid tumor.
Kuh HJ; Jang SH; Wientjes MG; Weaver JR; Au JL
J Pharmacol Exp Ther; 1999 Aug; 290(2):871-80. PubMed ID: 10411604
[TBL] [Abstract][Full Text] [Related]
22. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
23. Effects of hypotonic and hypoionic media on drug pumping by P-glycoprotein expressed in epithelial and nonepithelial cell lines.
Ambasch K; Cabantchik ZI; Slotki IN
J Cell Physiol; 1995 Jul; 164(1):117-22. PubMed ID: 7790383
[TBL] [Abstract][Full Text] [Related]
24. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
[TBL] [Abstract][Full Text] [Related]
26. Determinants of paclitaxel uptake, accumulation and retention in solid tumors.
Jang SH; Wientjes MG; Au JL
Invest New Drugs; 2001 May; 19(2):113-23. PubMed ID: 11392446
[TBL] [Abstract][Full Text] [Related]
27. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
28. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization.
Batrakova EV; Li S; Vinogradov SV; Alakhov VY; Miller DW; Kabanov AV
J Pharmacol Exp Ther; 2001 Nov; 299(2):483-93. PubMed ID: 11602658
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
31. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.
Chen Y; Pant AC; Simon SM
Cancer Res; 2001 Nov; 61(21):7763-9. PubMed ID: 11691790
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
33. Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport?
Václavíková R; Boumendjel A; Ehrlichová M; Kovár J; Gut I
Bioorg Med Chem; 2006 Jul; 14(13):4519-25. PubMed ID: 16516478
[TBL] [Abstract][Full Text] [Related]
34. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
35. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
36. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
37. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
38. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic models for the saturable distribution of paclitaxel.
Karlsson MO; Molnar V; Freijs A; Nygren P; Bergh J; Larsson R
Drug Metab Dispos; 1999 Oct; 27(10):1220-3. PubMed ID: 10497151
[TBL] [Abstract][Full Text] [Related]
40. Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1.
Huang Y; Blower PE; Yang C; Barbacioru C; Dai Z; Zhang Y; Xiao JJ; Chan KK; Sadée W
Pharmacogenomics J; 2005; 5(2):112-25. PubMed ID: 15668728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
